Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;40(1):103-110.
doi: 10.1007/s00345-021-03816-0. Epub 2021 Aug 26.

The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy

Luigi Nocera  1   2 , Mike Wenzel  3   4 , Claudia Collà Ruvolo  3   5 , Christoph Würnschimmel  3   6 , Zhe Tian  3 , Giorgio Gandaglia  7 , Nicola Fossati  7 , Felix K H Chun  4 , Vincenzo Mirone  5 , Markus Graefen  6 , Fred Saad  3 , Shahrokh F Shariat  8   9   10   11   12   13 , Francesco Montorsi  7 , Alberto Briganti  7 , Pierre I Karakiewicz  3
Affiliations

The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy

Luigi Nocera et al. World J Urol. 2022 Jan.

Abstract

Background: Race/ethnicity may predispose to less favorable prostate cancer characteristics in intermediate risk prostate cancer (IR PCa) patients. We tested this hypothesis in a subgroup of IR PCa patients treated with radical prostatectomy (RP).

Methods: We relied on the Surveillance, Epidemiology and End Results 2004-2016. The effect of race/ethnicity was tested in univariable and multivariable logistic regression analyses predicting upstaging (pT3+/pN1) and/or upgrading (Gleason Grade Group [GGG] 4-5) at RP.

Results: Of 20,391 IR PCa patients, 15,050 (73.8%) were Caucasian, 2857 (14.0%) African-American, 1632 (8.0%) Hispanic/Latino and 852 (4.2%) Asian. Asian patients exhibited highest age (64 year), highest PSA (6.8 ng/ml) and highest rate of GGG3 (31.9%). African-Americans exhibited the highest percentage of positive cores at biopsy (41.7%) and the highest proportion of NCCN unfavorable risk group membership (54.6%). Conversely, Caucasians exhibited the highest proportion of cT2 stage (35.6%). In univariable analyses, Hispanic/Latinos exhibited the highest rates of upstaging/upgrading among all race/ethnicities, in both favorable and unfavorable groups, followed by Asians, Caucasians and African-Americans in that order. In multivariable analyses, Hispanic/Latino race/ethnicity represented an independent predictor of higher upstaging and/or upgrading in favorable IR PCa (odds ratio [OR] 1.27, p < 0.01), while African-American race/ethnicity represented an independent predictor of lower upstaging and/or upgrading in unfavorable IR PCa (OR 0.79, p < 0.001).

Conclusion: Race/ethnicity predisposes to differences in clinical, as well as in pathological characteristics in IR PCa patients. Specifically, even after full statistical adjustment, Hispanic/Latinos are at higher and African-Americans are at lower risk of upstaging and/or upgrading.

Keywords: African-American; Asian; Hispanic/Latino; PCa; SEER.

PubMed Disclaimer

References

    1. Fletcher SA, von Landenberg N, Cole AP et al (2020) Contemporary national trends in prostate cancer risk profile at diagnosis. Prostate Cancer Prostatic Dis 23:81–87 - DOI
    1. Reese AC, Pierorazio PM, Han M et al (2012) Contemporary evaluation of the National Comprehensive Cancer Network prostate cancer risk classification system. Urology 80:1075–1079 - DOI
    1. Serrano NA, Anscher MS (2016) Favorable vs unfavorable intermediate-risk prostate cancer: a review of the new classification system and its impact on treatment recommendations. Oncology 30:229–236 - PubMed
    1. Kane CJ, Eggener SE, Shindel AW et al (2017) Variability in outcomes for patients with intermediate-risk prostate cancer (Gleason Score 7, International Society of Urological Pathology Gleason Group 2–3) and implications for risk stratification: a systematic review. Eur Urol Focus 3:487–497 - DOI
    1. Preisser F, Cooperberg MR, Crook J et al (2020) Intermediate-risk prostate cancer: stratification and management. Eur Urol Oncol 3:270–280 - DOI

LinkOut - more resources